Form 8-K - Current report:
SEC Accession No. 0001213900-25-044875
Filing Date
2025-05-16
Accepted
2025-05-16 16:05:12
Documents
14
Period of Report
2025-05-16
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0242452-8k_ostherapies.htm   iXBRL 8-K 27997
2 PRESS RELEASE ISSUED BY OS THERAPIES INCORPORATED ON MAY 16, 2025 ea024245201ex99-1_ostherap.htm EX-99.1 26128
  Complete submission text file 0001213900-25-044875.txt   236485

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE ostx-20250516.xsd EX-101.SCH 3023
4 XBRL LABEL FILE ostx-20250516_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE ostx-20250516_pre.xml EX-101.PRE 22364
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0242452-8k_ostherapies_htm.xml XML 3811
Mailing Address 15825 SHADY GROVE ROAD SUITE 135 ROCKVILLE MD 20850
Business Address 15825 SHADY GROVE ROAD SUITE 135 ROCKVILLE MD 20850 410-297-7793
OS Therapies Inc (Filer) CIK: 0001795091 (see all company filings)

EIN.: 825118368 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42195 | Film No.: 25959035
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)